Literature DB >> 11897747

Is lithium still worth using? An update of selected recent research.

Ross J Baldessarini1, Leonardo Tondo, John Hennen, Adele C Viguera.   

Abstract

The treatment of bipolar disorder has seen greater innovation in the past decade than at any other time since the introduction of lithium and the neuroleptics a half-century ago. The place of lithium in contemporary psychiatric therapeutics has become controversial, calling for the present overview of research findings pertaining to its use in treating patients with bipolar disorder. Lithium, by itself, typically is inadequate for rapid control of acute mania; antipsychotics, divalproex, or potent sedatives are commonly used, with or without lithium, for this purpose. The special usefulness of lithium lies in long-term prevention of recurrences of mania and bipolar depression and in reducing risk of suicidal behavior. Lithium also may be beneficial in recurrent unipolar depression and is an effective adjunct for treatment-resistant depression. Expectations that prolonged untreated bipolar illness, multiple episodes, rapid cycling, or retreatment following discontinuation might routinely lead to lithium nonresponsiveness, and the belief that lithium is too toxic for use during pregnancy, have not been borne out by research. Lithium retains a substantial share of prescriptions for bipolar disorder and is inexpensive. No other treatment has performed as well as lithium in as many aspects of long-term care of bipolar disorder patients, and despite some risks and limitations, lithium remains the standard against which all proposed alternatives are compared.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897747

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  11 in total

1.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Evaluation of left ventricular systolic and diastolic functions in bipolar patients during lithium therapy.

Authors:  Cemil Zencir; Filiz A Ozdemiroglu; Mustafa Cetin; Sibel N Avcil; Mithat Selvi; Hasan Gungor; Cagdas Akgullu; Ebru Findikli; Gurkan Acar
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Treatment research in bipolar disorder: issues and recommendations.

Authors:  Ross J Baldessarini
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses.

Authors:  Catalina Lopez de Lara; Iris Jaitovich-Groisman; Cristiana Cruceanu; Firoza Mamdani; Véronique Lebel; Volodymyr Yerko; Angus Beck; L Trevor Young; Guy Rouleau; Paul Grof; Martin Alda; Gustavo Turecki
Journal:  Int J Neuropsychopharmacol       Date:  2010-07-29       Impact factor: 5.176

5.  Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study.

Authors:  Kaan Kora; Mete Saylan; Cengiz Akkaya; Nesrin Karamustafalioglu; Nesrin Tomruk; Aziz Yasan; Timucin Oral
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

6.  Initial depressive episodes affect the risk of suicide attempts in Korean patients with bipolar disorder.

Authors:  Vin Ryu; Duk-In Jon; Hyun Sang Cho; Se Joo Kim; Eun Lee; Eun Joo Kim; Jeong-Ho Seok
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

Review 7.  Early intervention in bipolar disorder, part II: therapeutics.

Authors:  Giacomo Salvadore; Wayne C Drevets; Ioline D Henter; Carlos A Zarate; Husseini K Manji
Journal:  Early Interv Psychiatry       Date:  2008-08       Impact factor: 2.732

Review 8.  Pharmacological treatment of adult bipolar disorder.

Authors:  Ross J Baldessarini; Leonardo Tondo; Gustavo H Vázquez
Journal:  Mol Psychiatry       Date:  2018-04-20       Impact factor: 15.992

9.  Aripiprazole in the acute and maintenance phase of bipolar I disorder.

Authors:  Melanie Zupancic; Misty L Gonzalez
Journal:  Ther Clin Risk Manag       Date:  2012-01-12       Impact factor: 2.423

10.  GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration.

Authors:  Raquel Gómez-Sintes; Félix Hernández; José J Lucas; Jesús Avila
Journal:  Front Mol Neurosci       Date:  2011-11-16       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.